공시 • Mar 05
Allergy Therapeutics plc Announces Consistent Biomarker Results Fromits Phase I/IIa PROTECT Trial Allergy Therapeutics plc announces consistent biomarker results fromits Phase I/IIa PROTECT trial, supporting the strong immunomodulating potential of the product. Increasing doses of VLP peanut were associated with a reduction compared to baseline in basophil sensitivity for whole peanut extract and Ara h2. Notably, at the higher dose, the reduction reached 376% (p=0.003) and 489% (p=0.04) for peanut and Ara h2 compared to placebo respectively. The functional assay measuring the main allergen (Ara h2) binding to the effector B-Cells (IgE-Fab) demonstrated a relevant downward dose response, reaching statistical significance for the higher dose of VLP Peanut. Both these positive outcomes in basophil sensitivity and IgE-FAB were associated with a strong dose-response in Ara h2-specific IgG change from baseline when comparing each of the cumulative doses with placebo, reaching statistical significance for all but the lowest dose compared to placebo reaching p=0.0005 for the higher dose. A reduction in wheal diameter was observed 1-month post treatment while placebo wheal diameter slightly increased consistent with the beneficial immunological shift seen across the full panel of efficacy biomarkers. 공시 • Jan 29
Allergy Therapeutics plc Announces Board and Executive Appointments Allergy Therapeutics plc at its AGM held on 29 January 2026 appointed Helge Weiner-Trapness as a Executive Director. 30 January 2026- the company announced the appointment of Helge Weiner-Trapness as Chief Strategy Officer. He also joins the Group's Board as an Executive Director. Helge has more than 30 years of experience across leading global investment banks in the US and Asia. He most recently served as Vice Chairman, Global Banking at HSBC Holdings plc (LSE: HSBA; HKG: 0005), one of the world's largest financial organizations which is dual-listed on the London Stock Exchange and the Hong Kong Stock Exchange. He was a Founding Partner of Hong Kong-based Quintus Partners, an independent financial advisory firm offering investment banking, strategic advisory and capital raising, particularly in the US and Asia. Earlier, he held senior roles at Barclays Bank, Asia Pacific Land, J.P. Morgan Securities and Goldman Sachs. In his newly created role as Chief Strategy Officer, Helge will drive Allergy Therapeutics' long-term growth strategy, including corporate development, partnership strategy and portfolio prioritisation as Allergy Therapeutics advances its next-generation pipeline and explores opportunities to deliver on its global ambitions. Allergy Therapeutics also announced that Lawrence Allen Wang will join the Company's Board as an independent Non-Executive Director. Lawrence has more than 20 years' experience across healthcare and investment roles. He currently serves as Chief Financial Officer of Adicon Clinical Laboratories Inc. (HKG: 9860), one of China's leading independent clinical laboratory service providers, where he played a key role in the company's financing and its listing on the Hong Kong Stock Exchange. Prior to Adicon, Lawrence held roles in private equity, asset management and investment banking groups, including positions at Vivo Capital, Primavera Capital, Macquarie Group and Goldman Sachs (Asia). 공시 • Jan 19
Allergy Therapeutics plc Provides Earnings Guidance for the Six Months Ended 31 December 2025 Allergy Therapeutics plc provided earnings guidance for the six months ended 31 December 2025. For the period, the group expects revenue to be £36.3 million (2024: £34.0 million), representing growth of 7% on a reported basis,or 3% on a constant currency basis. Overall Group sales for the full year ending 30 June 2026 are expected to exceed those achieved in the year ended 30 June 2025. 공시 • Jan 06
Allergy Therapeutics plc, Annual General Meeting, Jan 29, 2026 Allergy Therapeutics plc, Annual General Meeting, Jan 29, 2026. Location: the offices of cooley uk llp, 22 bishopsgate, ec2n 4bq, london United Kingdom 공시 • Jul 31
Allergy Therapeutics plc Announces Publication of Three Papers in the Journal Allergy That Strengthens the Evidence Base for Grass MATA MPL Allergen Immunotherapy Allergy Therapeutics announced the publication of three key publications in the journal Allergy supporting the efficacy, safety and quality-of-life effects of Grass MATA MPL, the Group's innovative subcutaneous immunotherapy (SCIT) candidate designed to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen. Allergy is the official journal of EAACI with an impact factor of 12.6, the highest-impact journal in the field of allergy and clinical immunology. A Marketing Authorisation Application to the Paul Ehrlich Institut in Germany is currently under review, following the Group's submission in November 2024. Should this result in regulatory approval, commercial launch of the product is anticipated in FY2026. Results from Allergy Therapeutics' G306 Phase III trial, which completed in November 2023, have been published by Zielen et al., showing that Grass MATA MPL met the primary endpoint, demonstrating a highly statistically significant reduction in the Combined Symptom & Medication Score (CSMS) of 20.3% (p=0.0005) compared to placebo over the peak pollen season. Furthermore, a meta-analysis of the two Phase III trials in the Grass MATA MPL programme (G306 and G309) has also been published by Zielenet al., whereby 674 adult subjects with allergic rhinitis and/or rhino-conjunctivitis were included. Furthermore, based on an anchor-based approach using the rhinitis quality-of-life questionnaire, an MCID of 16% and 0.22 points were justified as relative and absolute CSMS differences, respectively. Taken together, these three papers complete the publication cycle for the adult-phase of the clinical programme evaluating Grass MATA MPL. The Group's G308 long-term paediatric study evaluating Grass MATA MPL in a paediatric population is ongoing, and the first cohort of grass allergic patients has completed their first grass pollen season. Furthermore, a Meta-analysis of the two Phase 3 trials in the Grass MATAMPL programme (G306 andG309) has also been published By Zielen et al. whereby 674 adult subjects with allergy rhinitis and/or Rhino-conjunctivis were included. Furthermore, based On an anchor-based approach using The rhinitis quality-of thelife questionnaire, an MCIDof 16% and 0.22points were justified as relative and absoluteCSMS differences, respectively. taken together, these three papers complete The publication cycle for the adult- phase of the clinical programme evaluating grass MATA MPL. The group's G308 long-term pediatric study evaluating Grass MATA MP L in a paediatric population is continue, and the first cohort of Grass MATA MPL has completed their first grass allergy season. 공시 • Jul 21
Allergy Therapeutics plc Provides Revenue Guidance for the Second Half and Year Ended 30 June 2025 Allergy Therapeutics plc provided revenue guidance for the second half and year ended 30 June 2025. Revenue for second half is expected to be £21.0 million (second half 2024: £21.6 million), reflecting an earlier than expected impact of the approaching change in the German regulatory landscape, as the end of the TAV transition period is reached in 2026. This is expected to result in unregistered allergy treatments being withdrawn from the market and a shift to fully licensed products.
Revenue for the year ended 30 June 2025 is expected to be broadly flat at £55.0 million (2024: £55.2 million) based on actual foreign currency rates. 
